 SAN DIEGO, June 17, 2021 PRNewswire -- Viking Therapeutics, Inc. Viking NASDAQ: VKTX, a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced results from the companys Phase 1 single ascending dose SAD and multiple ascending dose MAD clinical trial of VK0214, a novel, orally available small molecule thyroid receptor beta TRβ agonist in development for the potential treatment for X-linked adrenoleukodystrophy X-ALD. In this study, VK0214 demonstrated encouraging safety and tolerability, as well as a predictable pharmacokinetic PK profile. 